Eli Lilly’s Foundayo Faces Post-Approval FDA Scrutiny Over Liver Safety Data from Ongoing Diabetes Trial.
admin Eli Lilly’s newly approved oral obesity medication, Foundayo (orforglipron), has been subjected to significant post-market...
Biotech, Pharma & Cancer Drug Development
Terremoto raises $108M to pursue development of drugs targeting AKT
California-based Terremoto Biosciences has successfully closed a substantial $75 million Series A financing round, positioning...
Beeline Medicines Debuts with $300 Million Funding and Bristol Myers Squibb Pipeline to Advance Precision Therapies for Autoimmune Diseases.
Emerging from stealth on Wednesday, April 15, 2026, Beeline Medicines announced its official launch, fortified...
Johnson & Johnson Exceeds Q1 Expectations with Robust Oncology Growth, Navigating Immunology Shifts
Johnson & Johnson, the global healthcare behemoth, announced a stellar first-quarter performance for 2026, significantly...
Filspari’s Clearance in FSGS Marks End of Winding Regulatory Journey and Unlocks Over $1 Billion Annual Revenue Opportunity
The recent clearance of Filspari (sparsentan) by the U.S. Food and Drug Administration (FDA) for...
Spyre Therapeutics’ SPY001 Shows ‘Best-in-Class’ Potential in Ulcerative Colitis Trial, Shares Soar
Spyre Therapeutics, a prominent player in the inflammatory bowel disease (IBD) landscape, announced groundbreaking early...
Menopause Emerges from the Shadows: Unpacking the $17 Billion Market Amidst Scientific Gaps and Systemic Underinvestment
The global health landscape is witnessing a profound shift as menopause, long relegated to hushed...
Major Overhaul of CDC’s ACIP Sparks Debate on Vaccine Policy, Concurrent with Key Biopharma Deals and RNA Therapeutic Advances
The Centers for Disease Control and Prevention (CDC) has formally published a new charter for...
Oricell Therapeutics Secures $110 Million in Pre-IPO Funding to Accelerate Groundbreaking Solid Tumor Cell Therapy Development
Shanghai-based Oricell Therapeutics, a burgeoning force in the biotechnology sector, has successfully closed a pre-initial...
FDA Rejects Replimune’s Melanoma Therapy Again Citing Unaddressed Study Concerns, Fueling Industry Debate
The U.S. Food and Drug Administration (FDA) has delivered a second significant blow to Replimune...
